Skip to main content
An official website of the United States government
Español
Government Funding Lapse
Because of a lapse in government funding, the information on this website may not be up to date, transactions submitted via the website may not be processed, and the agency may not be able to respond to inquiries until appropriations are enacted.

The NIH Clinical Center (the research hospital of NIH) is open. For more details about its operating status, please visit cc.nih.gov.

Updates regarding government operating status and resumption of normal operations can be found at opm.gov.

PF-00299804

A drug used to treat non-small cell lung cancer that has spread, has not already been treated, and has certain mutations (changes) in the EGFR gene. It is also being studied in the treatment of other types of cancer. PF-00299804 blocks certain proteins, which may help keep cancer cells from growing and may kill them. It is a type of tyrosine kinase inhibitor. Also called dacomitinib and Vizimpro.
More Information
Search NCI's Dictionary of Cancer Terms